{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477350817
| IUPAC_name = N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide
| synonyms=EMD-61753
| image = Asimadoline structure.png
| width = 240
<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| index_label = 
| index2_label =
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 153205-46-0
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 179340
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D0VK52NV5M
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1190199
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 156107
| smiles = CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4
| smiles2 = O=C(N(C)[C@@H](c1ccccc1)CN2CC[C@H](O)C2)C(c3ccccc3)c4ccccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H30N2O2/c1-28(25(21-11-5-2-6-12-21)20-29-18-17-24(30)19-29)27(31)26(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,24-26,30H,17-20H2,1H3/t24-,25+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JHLHNYVMZCADTC-LOSJGSFVSA-N
<!--Chemical data-->
| C=27 | H=30 | N=2 | O=2
| molecular_weight = 414.539 g/mol
}}

'''Asimadoline''' ('''EMD-61753''') is a drug which acts as a peripherally selective [[kappa opioid receptor|κ-opioid receptor]] (KOR) [[agonist]].<ref name="pmid15989506">{{cite journal |author=Barber A, Gottschlich R |title=Novel developments with selective, non-peptidic kappa-opioid receptor agonists |journal=Expert Opinion on Investigational Drugs |volume=6 |issue=10 |pages=1351–68 |date=October 1997 |pmid=15989506 |doi=10.1517/13543784.6.10.1351 |url=|last2=Gottschlich }}</ref><ref name="pmid18715494">{{cite journal |author=Camilleri M |title=Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation |journal=Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society |volume=20 |issue=9 |pages=971–9 |date=September 2008 |pmid=18715494 |pmc=2698012 |doi=10.1111/j.1365-2982.2008.01183.x |url=}}</ref> Because of its poor ability to cross the [[blood–brain barrier]], asimadoline lacks the [[psychotomimetic]] effects of centrally acting KOR agonists, and consequently has more potential for medical use, and has been researched as a possible treatment for [[irritable bowel syndrome]], with reasonable efficacy seen in [[clinical trial]]s.<ref name="pmid15233705">{{cite journal |vauthors=Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J |title=Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome |journal=Alimentary Pharmacology & Therapeutics |volume=20 |issue=2 |pages=237–46 |date=July 2004 |pmid=15233705 |doi=10.1111/j.1365-2036.2004.01922.x |url=}}</ref><ref name="pmid17900994">{{cite journal |vauthors=Szarka LA, Camilleri M, Burton D, Fox JC, McKinzie S, Stanislav T, Simonson J, Sullivan N, Zinsmeister AR  |title=Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome |journal=Clinical Gastroenterology and Hepatology |volume=5 |issue=11 |pages=1268–75 |date=November 2007 |pmid=17900994 |pmc=2128734 |doi=10.1016/j.cgh.2007.07.011 |url=  }}</ref>

==Synthesis==
[[File:Asimadoline.png|500px]]

==See also==
* [[Eluxadoline]]
* [[Fedotozine]]
* [[Nalfurafine]]
* [[Trimebutine]]

==References==
{{Reflist|2}}

{{Drugs for functional gastrointestinal disorders}}
{{Opioidergics}}

[[Category:Synthetic opioids]]
[[Category:Kappa agonists]]
[[Category:Pyrrolidines]]
[[Category:Acetamides]]
[[Category:Peripherally selective drugs]]